ARTICLE | Clinical News

INT131: Phase IIa data

June 16, 2008 7:00 AM UTC

In a double-blind Phase lla trial (T-131-004) in 69 patients, both 1 and 10 mg of daily INT131 met the primary endpoint of a significant reduction in FPG from baseline to week 4. The mean change from ...